CTOs on the Move

FEI Systems

www.feisystems.com

 
FEI Systems is a leading IT company specializing in Federal and Local Government data system solutions, and for the past decade we have maintained a leading position in providing programming and consulting services in our primary areas of expertise- Behavioral Health Data Systems, and Clinical Trials Software Solutions for institutional systems of care. At the heart of our success you`ll find a talented team of experts who have helped our customers bridge the gap between the business needs of their organization, and the application of technologies required to successfully manage them.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.feisystems.com
  • 9755 Patuxent Woods Drive Suite 300
    Columbia, MD USA 21046
  • Phone: 443.270.5100

Executives

Name Title Contact Details

Similar Companies

Juneau Biosciences

Juneau Biosciences is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nanopartz

Nanopartz is a Loveland, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MethylGene

MethylGene Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Be Biopharma

Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.

Repare Therapeutics

Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare`s platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics.